Logo

Merck & Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies

Share this
Merck & Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies

Merck & Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies

Shots:

  • Taiho and Astex to receive $50M up front- up to $2.5B milestones based on preclinical- clinical- regulatory and sales plus royalties on sales. Merck (MSD outside the United States and Canada) to get exclusive worldwide rights to commercialize Taiho and Astex’s therapies and will also fund the R&D activities
  • Additionally- the companies will combine their respective preclinical candidate plus the data with knowledge and expertise from their respective research programs. Taiho to get co-commercialization rights in Japan with an option to promote in certain areas of South East Asia
  • The companies are focused on the development of multiple targeted therapies including KRAS oncogene- further accelerating the global R&D of therapies which are targeted to treat cancer

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Twitter


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions